Exagen is focused on transforming care for patients with debilitating and chronic autoimmune diseases by enabling timely differential diagnosis, prognosis, and monitoring. The company commercializes a portfolio of testing products under its AVISE brand, several of which are based on its proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess activation of the complement system, a pathway implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Exagen launched a therapeutics promotion business earlier this year and intends to continue growing its testing business by commercializing products in its R&D pipeline and expanding its sales force footprint. Its flagship test, AVISE CTD, has been ordered over 300,000 times since its 2012 launch. The company’s business model integrates testing products and therapeutics to offer targeted solutions to rheumatologists and better serve patients. Exagen Diagnostics is a commercial-stage specialty diagnostics company based in Vista, CA and Albuquerque, NM that focuses on autoimmune connective tissue diseases. It operates a College of American Pathologists (CAP)–accredited, CLIA‑certified rheumatology specialty laboratory led by CEO Ron Rocca. The company commercializes proprietary Cell Bound Complement Activation Products (CB-CAPs) technology and a suite of AVISE® tests for diagnosis, prognosis and monitoring of conditions such as SLE, RA and APS. Its AVISE portfolio includes disease-specific assays (AVISE CTD, AVISE SLE Prognostic, AVISE SLE Monitor, AVISE APS) and therapeutic drug monitoring tests (AVISE MTX, AVISE HCQ). Exagen received up to $25M in debt financing in the form of term loans provided by an affiliate of Innovatus Capital Partners. The company intends to use the funds to accelerate commercialization of its CB-CAPs technology. Exagen Diagnostics is a commercial-stage specialty diagnostic company that develops and commercializes novel diagnostic products to enable physicians to accurately diagnose patients. The company operates a CLIA-certified, CAP-accredited laboratory in Vista, Calif., and maintains corporate offices in Albuquerque, N.M. Leadership includes Ron Rocca (president and CEO) and Curt LaBelle, M.D. (chairman of Exagen and managing director at Tullis Health Investors). Exagen recently raised equity capital to support its growth. The company intends to use proceeds for market expansion and development of near-term pipeline products. No operating metrics beyond the fundraising and locations were provided in the article.

Total raised

$53M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2019